Recruiting
Phase 1/2
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Condition(s) studied
Advanced/Metastatic Solid TumorsColorectal CancerGastric CancerGastroesophageal-junction CancerNSCLCHNSCCHead and Neck Squamous Cell CarcinomaEsophageal Cancer
Investigational drug(s) / intervention(s)
MCLA-158 →MCLA-158 + PembrolizumabMCLA-158 + FOLFIRIMCLA-158 + FOLFOX
MCLA-158: full-length IgG1 bispecific antibody targeting EGFR and LGR5
MCLA-158 + Pembrolizumab: MCLA-158 in combination with pembrolizumab will be explored first in HNSCC patients eligible to receive pembrolizumab as first-line monotherapy.
MCLA-158 + FOLFIRI: MCLA-158 in combination with FOLFIRI will be explored in mCRC patients with up to 1 line of prior regimen.
MCLA-158 + FOLFOX: MCLA-158 in combination with FOLFOX will be explored in mCRC patients with up to 1 line of prior regimen.
Study summary
This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC.
The dose escalation part has been completed and the RP2D will be further evaluated in an expansion part of the study. Cohorts of selected solid tumor indications for which there is evidence of EGFR dependency and potential sensitivity to EGFR inhibition will be evaluated including head and neck cancer and metastatic colorectal cancer (mCRC).
The study will further assess the safety, tolerability, PK, PD, immunogenicity, and anti-tumor activity of MCLA-158 in monotherapy or in combination with other therapies.
Eligibility
Inclusion Criteria:
* Histologically or cytologically confirmed solid tumors with evidence of metastatic or locally advanced disease not amenable to standard therapy with curative intent.
* A baseline fresh tumor sample (FFPE) from a metastatic or primary site (if safe/feasible).
* Amenable for biopsy (if safe/feasible).
* Measurable disease as defined by RECIST version 1.1 by radiologic methods.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
* Life expectancy ≥ 12 weeks, as per investigator.
* Left ventricular ejection fraction (LVEF) ≥ 50% by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA).
* Adequate organ function
* Expansion cohorts: patients with locally advanced unresectable or metastatic disease for the following indications:
SINGLE AGENT:
* SECOND-/THIRD-LINE HNSCC PATIENTS (cohort closed to enrolment): patients who have progressed on or after, or are intolerant to, anti-PD-(L)1 therapy and platinum therapy as monotherapy or in combination with other agents and no previous exposure to EGFR inhibitors. Patients treated with platinum-containing therapy only in the adjuvant setting, or in the context of multimodal therapy for locally advanced disease should have disease progression within 6 months of the last dose of platinum containing therapy. Patients with no more than 2 prior lines of treatment in recurrent or metastatic disease. • Human papilloma virus (HPV) status determined by p16 immunohistochemistry (IHC) or molecular HPV test for all oropharyngeal tumors should be reported when available.
* The eligible HNSCC primary tumor locations are oropharynx, oral cavity, hypopharynx, and larynx.
* 3L+ mCRC (cohort open to enrolment) patients must have:
* No oncogenic missense mutations in KRAS, NRAS, BRAF, or EGFR ectodomain, and no HER2 (ERBB2) or KRAS amplification, as detected in plasma by ctDNA NGS central testing performed during screening.
* A microsatellite stable (MSS) tumor.
* Received ≥2 and no more than 4 lines of prior therapy in the metastatic setting including:
1. Chemotherapy with oxaliplatin, irinotecan, and a fluoropyrimidine,
2. Targeted therapy with an anti-VEGF therapy
COMBINATION:
* FIRST-LINE HNSCC (cohort closed to enrolment): patients eligible to receive pembrolizumab as first-line monotherapy with tumors expressing programmed cell death protein ligand 1 (PD-L1), combined positive score (CPS) ≥1, as determined by a Food and Drug Administration (FDA) approved test in the US, or by an approved equivalent test in other countries; patients should not have previous systemic therapy administered in the recurrent or metastatic setting, although previous systemic therapy as part of multimodal treatment for locally advanced disease is allowed if ended ≥6 months prior to signing the ICF. The eligible HNSCC primary tumor locations are oropharynx, oral cavity, hypopharynx, and larynx. Previous treatments with anti PD-(L)1 or anti-EGFR therapies are not allowed.
* mCRC (cohorts open to enrolment): Patients should have been previously diagnosed with histologically or cytologically confirmed unresectable or metastatic adenocarcinoma of the colon or rectum. Patients must be RAS/ RAF WT as determined using tumor tissue (primary or metastatic) by an appropriate tumor tissue based assay, to be confirmed by the sponsor, and must have an MSS tumor. Patients must be naive to prior anti-EGFR therapy.
i. Cohort to be treated with petosemtamab and FOLFIRI: patients may have received up to 1 prior chemotherapy regimen for the metastatic setting, consisting of 1L fluoropyrimidine-oxaliplatin-based chemotherapy ± bevacizumab.
ii. Cohort to be treated with petosemtamab and FOLFOX: patients may have received up to 1 prior chemotherapy regimen in the metastatic setting consisting of 1L fluoropyrimidine-irinotecan-based chemotherapy ± bevacizumab
Exclusion Criteria:
* Central nervous system metastases that are untreated or symptomatic, or require radiation, surgery, or continued steroid therapy to control symptoms within 14 days of study entry.
* Known leptomeningeal involvement.
* Participation in another clinical study or treatment with any investigational drug within 4 weeks prior to study entry.
* Any systemic anticancer therapy within 4 weeks or 5 half-lives whichever is shorter of the first dose of study treatment. For cytotoxic agents that have major delayed toxicity ( e.g. mitomycin C,nitrosoureas), or anticancer immunotherapies, a washout period of 6 weeks is required.
* Requirement for immunosuppressive medication (e.g. methotrexate, cyclophosphamide)
* Major surgery or radiotherapy within 3 weeks of the first dose of study treatment. Patients who received prior radiotherapy to ≥25% of bone marrow are not eligible, irrespective of when it was received.
* Persistent grade \>1 clinically significant toxicities related to prior antineoplastic therapies (except for alopecia); stable sensory neuropathy ≤ grade 2 NCI-CTCAE v4.03 is allowed.
* History of hypersensitivity reaction to any of the excipients of petosemtamab, human proteins or any non-IMP treatment required for this study.
* Uncontrolled hypertension (systolic blood pressure \[BP\] \> 150 mmHg and/or diastolic BP \> 100 mmHg) with appropriate treatment or unstable angina. History of congestive heart failure of Class II-IV New York Heart Association (NYHA) criteria, or serious cardiac arrhythmia requiring treatment (except atrial fibrillation, paroxysmal supraventricular tachycardia). History of myocardial infarction within 6 months of study entry.
* History of prior malignancies with the exception of excised cervical intraepithelial neoplasia or nonmelanoma skin cancer, or curatively treated cancer deemed at low risk for recurrence with no evidence of disease for 3 years.
* Current dyspnea at rest of any origin, or other diseases requiring continuous oxygen therapy. Patients with a history of interstitial lung disease (e.g., pneumonitis or pulmonary fibrosis) or evidence of ILD on baseline chest computerized tomography (CT) scan.
* Current serious illness or medical conditions including, but not limited to uncontrolled active infection,clinically significant pulmonary, metabolic or psychiatric disorders.
* Patients with known infectious diseases:
i. Active hepatitis B infection (hepatitis B surface antigen \[HBsAg\] positive) without receiving antiviral treatment.
ii. Positive test for hepatitis C ribonucleic acid (HCV) RNA).
• Pregnant or breastfeeding patients; patients of childbearing potential must use highly effective contraception methods prior to study entry, for the duration of study participation, and for 6 months after the last dose of MCLA-158.
Primary outcome measure(s)
- Escalation: Number of patients with Dose Limiting Toxicities (DLTs) during Cycle 1 — 4 weeks
Evaluation of the number and severity of participants with treatment related toxicities observed during the dose escalation.
- Expansion (Single agent - randomized expansion in 2/3L Head and Neck cancer, and combination cohorts): Safety and tolerability: AEs and SAEs — 6-12 months
Incidence, severity, and relationship of AEs and SAEs
- Expansion (Single agent - randomized expansion in 2/3L Head and Neck cancer): Treatment discontinuations and dose modifications due to AEs — 6-12 months
Treatment discontinuations due to AEs and dose modifications due to AEs
- Expansion (single agent - randomized expansion in 2/3L Head and Neck cancer): Best overall response (BOR) — 36 months
Evaluation of clinical benefit assessed by RECIST v1.1 determining Best overall response (BOR)
- Expansion (Single agent - non-randomized, and combination cohorts): Objective response rate (ORR) — 36 months
Evaluation of clinical benefit assessed by RECIST v1.1 determining objective response rate (ORR)
- Expansion (single agent - randomized expansion in 2/3L Head and Neck cancer): exposure-safety relationship of petosemtamab administered at 1100 mg and 1500 mg: TEAEs — 8 weeks
Incidence of TEAEs at Week 8
- Expansion: (mCRC subcutaneous cohort): Bioavailability of subcutaneous vs intravenous administration — 6 weeks
Bioavailability of subcutaneous vs intravenous administration
- Expansion: (mCRC subcutaneous cohort): Area under the concentration versus time curve from time zero to time t [AUC0-t] — 6 weeks
Area under the concentration versus time curve from time zero to time t \[AUC0-t\]
- Expansion: (mCRC subcutaneous cohort): Maximum plasma concentration [Cmax] — 8 weeks
Maximum plasma concentration as measured from all individual plasma concentrations
- Expansion: (mCRC subcutaneous cohort): Minimum plasma drug concentration [Ctrough] — 6 weeks
Minimum plasma concentration as measured from all individual plasma concentrations
Trial sites (54)
| Facility | City | Region | Status |
| UCSD |
La Jolla |
California |
Recruiting |
| USC Norris Comprehensive Cancer Center |
Los Angeles |
California |
Active Not Recruiting |
| Sharp Healthcare |
San Diego |
California |
Recruiting |
| Rocky Mountain Cancer Centers |
Lone Tree |
Colorado |
Recruiting |
| Florida Cancer Specialists |
Fort Myers |
Florida |
Active Not Recruiting |
| University of Florida |
Gainesville |
Florida |
Recruiting |
| Sarah Cannon Research Institute (Lake Nona) |
Orlando |
Florida |
Recruiting |
| Emory University |
Atlanta |
Georgia |
Recruiting |
| Massachusetts General Hospital - Dana Farber |
Boston |
Massachusetts |
Recruiting |
| Karmanos Cancer Institute |
Detroit |
Michigan |
Completed |
| SSM Health Saint Louis University Hospital |
St Louis |
Missouri |
Completed |
| Washington University School of Medicine at St Louis |
St Louis |
Missouri |
Recruiting |
| Cayuga Medical Center |
Ithaca |
New York |
Recruiting |
| Mt. Sinai |
New York |
New York |
Recruiting |
| Memorial Sloan Kettering Cancer Center |
New York |
New York |
Recruiting |
| Hematology-Oncology Associates of Central New York |
Syracuse |
New York |
Recruiting |
| Cleveland Clinic |
Cleveland |
Ohio |
Recruiting |
| Ohio State University |
Columbus |
Ohio |
Recruiting |
| Taylor Cancer Research Center |
Maumee |
Ohio |
Recruiting |
| SSM OKC Hightower Clinical |
Oklahoma City |
Oklahoma |
Recruiting |
| University of Pennsylvania |
Philadelphia |
Pennsylvania |
Recruiting |
| The University Of Tennessee Health Science Center |
Memphis |
Tennessee |
Recruiting |
| Sarah Cannon Research Institute |
Nashville |
Tennessee |
Completed |
| Texas Oncology |
Dallas |
Texas |
Recruiting |
| Oncology Consultants |
Houston |
Texas |
Recruiting |
| Texas Oncology |
Tyler |
Texas |
Recruiting |
| Utah Cancer Specialists |
Salt Lake City |
Utah |
Recruiting |
| University of Utah Health Huntsman Cancer Hospital |
Salt Lake City |
Utah |
Recruiting |
| Oncology & Hematology Associates of Southwest Virginia |
Roanoke |
Virginia |
Recruiting |
| Georgetown University Medical Center |
Georgetown |
Washington |
Recruiting |
| Cancer Care Northwest |
Spokane |
Washington |
Recruiting |
| Cliniques universitaires Saint-Luc |
Brussels |
Belgium |
Recruiting |
| Institut Jules Bordet |
Brussels |
Belgium |
Completed |
| UZ Gent |
Ghent |
Belgium |
Recruiting |
| Chu Ucl Namur Site De Sainte-Elisabeth |
Namur |
Belgium |
Recruiting |
| Hopital Saint Andre, CHU Bordeaux |
Bordeaux |
France |
Recruiting |
| Centre Leon Berard |
Lyon |
France |
Recruiting |
| Hopital La Timone |
Marseille |
France |
Recruiting |
| Institut Régional du Cancer de Montpellier |
Montpellier |
France |
Recruiting |
| Centre Antoine Lacassagne |
Nice |
France |
Recruiting |
+ 14 more sites — see the full list on the official registry below.
More Merus B.V. trials in the Netherlands
Other trials for the same condition